Nomenclature and heterogeneity: consequences for the use of mesenchymal stem cells in regenerative medicine

Alison Jane Wilson; Andrew Joseph Webster; Paul Gilbert Genever

doi:10.2217/rme-2018-0145

Nomenclature and heterogeneity: consequences for the use of mesenchymal stem cells in regenerative medicine

Alison Jane Wilson, Andrew Joseph Webster, Paul Gilbert Genever

Research output: Contribution to journal › Article › peer-review

Abstract

Mesenchymal stem cells (MSCs) are in development for many clinical indications, based both on “stem” properties (tissue repair or regeneration) and on signalling repertoire (immunomodulatory and anti-inflammatory effects). Potential conflation of MSC properties with those of tissue-derived stromal cells presents difficulties in comparing study outcomes and represents a source of confusion in cell therapy development. Cultured MSCs demonstrate significant heterogeneity in clonogenicity and multi-lineage differentiation potential. However in vivo biology of MSCs includes native functions unrelated to regenerative medicine applications, so do nomenclature and heterogeneity matter? In this perspective we examine some consequences of the nomenclature debate and heterogeneity of MSCs. Regulatory expectations are considered, emphasising that product development should prioritise detailed characterisation of therapeutic cell populations for specific indications.

Original language	English
Pages (from-to)	595-611
Journal	REGENERATIVE MEDICINE
Volume	14
Issue number	6
Early online date	22 May 2019
DOIs	https://doi.org/10.2217/rme-2018-0145
Publication status	Published - 1 Jun 2019

Bibliographical note

Access to Document

10.2217/rme-2018-0145

Nomenclature and heterogeneity: consequences for the use of mesenchymal stem cells in regenerative medicine
© 2019 AJ Wilson, AJ Webster, PG Genever
Final published version, 918 KBLicence: CC BY

Cite this

@article{57bdd57fc9364486b989828322eb7999,

title = "Nomenclature and heterogeneity: consequences for the use of mesenchymal stem cells in regenerative medicine",

abstract = "Mesenchymal stem cells (MSCs) are in development for many clinical indications, based both on “stem” properties (tissue repair or regeneration) and on signalling repertoire (immunomodulatory and anti-inflammatory effects). Potential conflation of MSC properties with those of tissue-derived stromal cells presents difficulties in comparing study outcomes and represents a source of confusion in cell therapy development. Cultured MSCs demonstrate significant heterogeneity in clonogenicity and multi-lineage differentiation potential. However in vivo biology of MSCs includes native functions unrelated to regenerative medicine applications, so do nomenclature and heterogeneity matter? In this perspective we examine some consequences of the nomenclature debate and heterogeneity of MSCs. Regulatory expectations are considered, emphasising that product development should prioritise detailed characterisation of therapeutic cell populations for specific indications. ",

author = "Wilson, {Alison Jane} and Webster, {Andrew Joseph} and Genever, {Paul Gilbert}",

note = "{\textcopyright} 2019 AJ Wilson, AJ Webster, PG Genever ",

year = "2019",

month = jun,

day = "1",

doi = "10.2217/rme-2018-0145",

language = "English",

volume = "14",

pages = "595--611",

journal = "REGENERATIVE MEDICINE",

issn = "1746-0751",

publisher = "Future Medicine Ltd.",

number = "6",

}

TY - JOUR

T1 - Nomenclature and heterogeneity

T2 - consequences for the use of mesenchymal stem cells in regenerative medicine

AU - Wilson, Alison Jane

AU - Webster, Andrew Joseph

AU - Genever, Paul Gilbert

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Mesenchymal stem cells (MSCs) are in development for many clinical indications, based both on “stem” properties (tissue repair or regeneration) and on signalling repertoire (immunomodulatory and anti-inflammatory effects). Potential conflation of MSC properties with those of tissue-derived stromal cells presents difficulties in comparing study outcomes and represents a source of confusion in cell therapy development. Cultured MSCs demonstrate significant heterogeneity in clonogenicity and multi-lineage differentiation potential. However in vivo biology of MSCs includes native functions unrelated to regenerative medicine applications, so do nomenclature and heterogeneity matter? In this perspective we examine some consequences of the nomenclature debate and heterogeneity of MSCs. Regulatory expectations are considered, emphasising that product development should prioritise detailed characterisation of therapeutic cell populations for specific indications.

AB - Mesenchymal stem cells (MSCs) are in development for many clinical indications, based both on “stem” properties (tissue repair or regeneration) and on signalling repertoire (immunomodulatory and anti-inflammatory effects). Potential conflation of MSC properties with those of tissue-derived stromal cells presents difficulties in comparing study outcomes and represents a source of confusion in cell therapy development. Cultured MSCs demonstrate significant heterogeneity in clonogenicity and multi-lineage differentiation potential. However in vivo biology of MSCs includes native functions unrelated to regenerative medicine applications, so do nomenclature and heterogeneity matter? In this perspective we examine some consequences of the nomenclature debate and heterogeneity of MSCs. Regulatory expectations are considered, emphasising that product development should prioritise detailed characterisation of therapeutic cell populations for specific indications.

U2 - 10.2217/rme-2018-0145

DO - 10.2217/rme-2018-0145

M3 - Article

SN - 1746-0751

VL - 14

SP - 595

EP - 611

JO - REGENERATIVE MEDICINE

JF - REGENERATIVE MEDICINE

IS - 6

ER -